ThinkEquity Initiates Coverage on Clarient (CLRT) with a Buy
More News related to CLRT
- Clarient (CLRT) Reports Positive Results from Ovotax Assay
- New Data Indicate Effectiveness of Clarient's Ovotax(TM) Test for Ovarian Cancer
- Clarient, Inc. (CLRT) Posts Q4 Loss of $0.03, Wider than Views; Guides FY10 Revs
- Clarient Reports 2009 Fourth Quarter; Year-End Results
- Clarient CEO Ron Andrews to Present at the Roth Annual OC Growth Stock Conference in Dana Point, CA
More News related to New Coverage
- Top 10 News Items 3/15-3/19: PPI/CPI Data Soothes Inflation Worries, Fed Leaves Rates Unchanged, Boeing to Accelerate Production of 777's, 747's
- Trading Radar for 03/19: Williams Sonoma (WSM), Tiffany & Co. (TIF), Phillips-Van Heusen (PVH), GigaMedia (GIGM) Report
- Notable ETF Movers 3/19: UUP, VXX, THD Up; XLE, USO, TAN, SMH Down
- Unusual 11 Mid-Day Movers 3/19: GENT, CTEL, POL, CNAM, LYG Higher; APPA, ADUS, PALM, BBX Lower
- Notable Mergers and Acquisitions of the Day 03/19: LGF, MORN, DMND
ThinkEquity initiates coverage on Clarient (Nasdaq: CLRT) with a Buy.
To see all the upgrades/downgrades on shares of CLRT, visit our Analyst Ratings page.
Clarient, Inc. (Clarient) is an oncology diagnostics services company.
Related Categories
New CoverageStocks Mentioned
-0.04Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
